医学
骨质疏松症
造血干细胞移植
骨矿物
移植
内科学
骨密度
人口
骨科手术
重症监护医学
外科
环境卫生
作者
David L. Kendler,Jean–Jacques Body,Maria Luisa Brandi,Raewyn Broady,Jorge B. Cannata‐Andía,M. J. Cannata-Ortiz,A. El Maghraoui,Giuseppe Guglielmi,Peyman Hadji,Dominique D. Pierroz,T. J. de Villiers,René Rizzoli,Peter R. Ebeling,Bone Disease
标识
DOI:10.1007/s00198-018-4669-4
摘要
Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for patients with some malignant and non-malignant hematological diseases. Advances in transplantation techniques and supportive care measures have substantially increased the number of long-term HSCT survivors. This has led to an increasing patient population suffering from the late effects of HSCT, of which, bone loss and its consequent fragility fractures lead to substantial morbidity. Altered bone health, with consequent fragility fractures, and chronic graft-versus-host disease (GVHD) are factors affecting long-term quality of life after HSCT. Hypogonadism, HSCT preparative regimens, nutritional factors, and glucocorticoids all contribute to accelerated bone loss and increased fracture risk. Management strategies should include bone mineral density examination, evaluation of clinical risk factors, and general dietary and physical activity measures. Evidence has accumulated permitting recommendations for more attentiveness to evaluation and monitoring of bone health, with appropriate application of osteoporosis pharmacotherapies to patients at increased risk of bone loss and fracture.
科研通智能强力驱动
Strongly Powered by AbleSci AI